Striatal dopamine does not appear involved in the voluntary intake of ethanol by rats

Daoust, M.; Moore, N; Saligaut, Christian; Lhuintre, J. P.; Chrétien, Pierre; Boismare, F

doi:10.1016/0741-8329(86)90065-0

Cited by 14 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Acamprosate, like naltrexone, reduced alcohol drinking under limited access conditions (Olive et al, 2002). Acamprosate's effects were greatly diminished under continuous access conditions (Stromberg et al, 2001) unless rats screened for high ethanol preference were tested (Boismare et al, 1984;Daoust et al, 1987). Acamprosate administration minimally affected operant behavior maintained by ethanol delivery in Wistar rats with a limited history of alcohol exposure (Stromberg et al, 2001;Heyser et al, 2003).…”

Section: Introductionmentioning

confidence: 99%

Can experimental paradigms and animal models be used to discover clinically effective medications for alcoholism?

Egli

2005

Addiction Biology

View full text Add to dashboard Cite

Evaluating medications in animal laboratory paradigms can reveal whether the compound is effective in an established alcoholism model, at clinically relevant doses and exposure conditions, when administered orally (or transdermally) and without serious limiting side effects. Positive outcomes constitute a possible discovery for relevance to alcoholism and, under favorable marketing conditions, encourage further development. Medication testing using animal models of alcoholism might also guide clinical testing by discriminating clinically effective from clinically ineffective compounds. This ability rests on whether there are tests or, more reasonably, batteries of tests having this discriminative ability. The present paper examines this possibility. Effects of naltrexone and acamprosate in animal paradigms which model behavioral aspects of alcoholism are reviewed and compared with the effects of compounds which have limited effects in alcoholics. It is not clear at present whether any single paradigm or combination of paradigms differentiates clinically effective from clinically limited compounds. Steps are suggested to improve the use of preclinical laboratory tests to predict which compounds are likely to be effective medications for reducing drinking and sustaining abstinence in human alcoholics.

show abstract

Section: Introductionmentioning

confidence: 99%

Can experimental paradigms and animal models be used to discover clinically effective medications for alcoholism?

Egli

2005

Addiction Biology

View full text Add to dashboard Cite

show abstract

“…It was shown that acamprosate binds preferentially to GABA B receptors 1,2 and administration of the drug enhanced synaptosomal [ 3 H]GABA uptake. 3 Results of electrophysiological studies and the finding that acamprosate restores the GABA basal concentration in alcoholdependent rats support the GABA hypothesis.…”

Section: Introductionmentioning

confidence: 99%